Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Drug efficacy

Marijuana liquid may play a medicinal role in epilepsy

Treatment with cannabidiol, an extract of marijuana, reduces seizure frequency for patients with certain epilepsy conditions, new research suggests. In the image, a cannabis plant


Cannabidiol, an extract of marijuana, showed reductions in seizure frequency for patients with certain epilepsy conditions

Cannabidiol is an extract of marijuana that has no psychoactive properties but potential medicinal uses, including as an anticonvulsant. To explore this possibility, ten centres in the United States have been granted permission to use a liquid form of cannabidiol (Epidiolex, GW Pharmaceuticals) in children and young adults with severe treatment-resistant epilepsy.

At the American Academy of Neurology’s annual meeting, researchers presented data[1] on 123 such patients, whose aetiologies included Dravet syndrome and Lennox-Gastaut syndrome. After 12 weeks’ treatment with cannabidiol at a daily dose of up to 25mg/kg, total seizures (convulsive and nonconvulsive) fell by 46%, on average, versus baseline. The most common adverse events were somnolence, diarrhoea, fatigue and decreased appetite.

“Controlled trials are indicated to characterise efficacy and safety,” the researchers conclude. 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20068364

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.